Translation and Commercialisation
Our translation and commercialisation office works closely with Centenary scientists to progress research discoveries towards the development of new treatments. Centenary actively engages with pharmaceutical and biotech companies, investors and other academic collaborators globally.
Innovations
Centenary strives to deliver improved health outcomes to patients. Centenary’s research expertise, capabilities and discoveries span a wide range of areas and indications.
Centre: Healthy Ageing
Indication: Alzheimer’s disease
Stage: Preclinical
Description: Therapy targeting a novel mechanism
Status: Licensed. Open to investment.
Centre: Infection & Immunity
Indication: COVID
Stage: Preclinical
Description: Novel composition and formulation
Status: Available to licence
Centre: Cancer Innovations
Indication: Diagnostic – aggressive cancers
Stage: Phase 1
Description: A novel tumour imaging agent for rapid assessment of treatment response
Status: Licensed
Centre: Rare Diseases & Gene Therapy
Indication: Genetic diseases
Stage: Preclinical
Description: Platform technology to increase efficiency and safety, and reduce cost of AAV gene therapies
Status: Available for licensing or investment via start-up AAVec Bio
Centre: Biomedical AI
Indication: Broad application
Stage:
Description: Directed evolution system to rapidly optimise selected properties of biologics
Status: Seeking collaborations
Centre: Rare Diseases & Gene Therapy
Indication: Broad application
Stage:
Description: Direct & quantifiable measurement of small molecule-target engagement
Status: Seeking collaborations
Centre: Cancer Innovations
Indication: Aggressive Cancers
Stage: Preclinical
Description: A novel radiotherapy for aggressive cancers
Status: Licensed
Centre: Infection & Immunity
Indication: Tuberculosis
Stage: Preclinical
Description: Novel compositions. Large head-2-head study of a range of antigens & adjuvants to select optimal composition
Status: Seeking investment
Research Journeys
-
Blood fats predict success of dietary weight loss in pre-diabetes management
New research from the Centenary Institute has identified specific blood fats that can predict how effectively individuals with pre-diabetes will improve their blood sugar levels through diet and weight loss. These findings could pave the way for more personalised approaches to preventing and managing type 2 diabetes.
-
New genetic tool predicts risk of liver disease in heavy drinkers
An international research group led by the Centenary Institute has developed a new genetic risk prediction tool to identify heavy drinkers most at risk of developing alcohol-associated cirrhosis, a severe form of liver disease.
-
New technology, ‘Invasion-Block’, targets melanoma spread
Research conducted at the Centenary Institute has given rise to a ground-breaking tool called ‘Invasion-Block’ that can identify drugs capable of halting the spread of cancer cells. The pioneering development could lead to better treatments for melanoma, the most dangerous form of skin cancer.
Contact
For enquires, contact:
Dr Katrina Frankcombe
Translation and Commercialisation Manager
Email: k.frankcombe@centenary.org.au
Phone: 02 9565 6266
